Sector News

Takeda US president quits

November 25, 2014
Life sciences
The president of Japanese drug major Takeda Pharmaceutical’s (TYO: 4502) US subsidiary, Douglas Cole, has resigned, after 22 years with the company.
 
Mr Cole, aged 47, “is at a point in his career where he decided to explore his options,” company spokeswoman Sandy Rodriguez told Crain’s Chicago Business. He plans to remain with the company until the end of its fiscal year, March 31, 2015, or until a successor is named.
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]